QNTM

Business Context and Reporting Period

Company: Quantum Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2025 (Filing Date: January 21, 2025)
Context: The filing incorporates by reference a Form 7 Monthly Progress Report filed with the Canadian Securities Exchange on January 7, 2025, detailing the closing of a private placement offering.

Key Financial Metrics

Capital Raised: $1,000,000 aggregate proceeds from a non-brokered private placement.
Instrument: Convertible Debenture Units (1,000 units issued at $1,000 per unit).
Debt Terms:

• Interest Rate: 1.25% per annum, payable in cash quarterly.
• Maturity: 36 months from issuance.
• Conversion Price: $6.25 per Class B subordinate voting share.

Warrant Terms:

• Quantity: 80 warrants per unit (80,000 total warrants).
• Exercise Price: $7.00 per share.
• Term: 5 years from issuance.

Liquidity and Cash Flow: The filing does not provide specific cash flow statements, current cash balances, or liquidity ratios. Proceeds are designated for ongoing business model development and general working capital.

Material Changes

The primary material change reported is the successful closing of the $1,000,000 Convertible Debenture Unit offering in December 2024. This represents a new source of debt financing with equity conversion features and warrant coverage, distinct from prior periods which are not detailed in this specific filing.

Guidance, Outlook, and Risks

Use of Proceeds: Funds will be utilized for the ongoing development of the Company's business model and general working capital purposes.
Regulatory Status: The offering was not registered under the U.S. Securities Act of 1933. No units were offered or sold in the United States or to U.S. persons.
Risks and Contingencies: The filing does not explicitly list new risk factors or contingencies beyond the standard terms of the convertible debt and warrants. The Company remains subject to the risks associated with its development stage and capital requirements.

Investor Verification Checklist

• Verify the exact closing date of the December 2024 offering to confirm interest accrual start dates.
• Confirm the current share count and potential dilution impact from the 80,000 warrants and potential conversion of $1,000,000 principal at $6.25/share.
• Review the attached Exhibit 99.1 (Form 7) for detailed financial statements not included in this summary.
• Assess the Company's ability to meet quarterly cash interest payments given its development stage.
• Confirm the status of the Form F-3 Registration Statement (File No. 333-276264) referenced for incorporation.